Market Overview:
The global amebiasis market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of amebiasis, increasing awareness about the disease, and growing demand for effective treatment options. Based on type, the global amebiasis market is segmented into metronidazole, paromomycin, tinidazole, and other drugs. Metronidazole is expected to account for the largest share of the global amebiasis market in 2018 owing to its high efficacy and safety profile. Paromomycin is also expected to witness significant growth during the forecast period due to its low cost and easy availability. Based on application, the global amebiasis market is segmented into hospitals and pharmacies.
Product Definition:
Amebiasis is an intestinal infection caused by the ameba Entamoeba histolytica. It is one of the most common parasitic infections in the world, affecting an estimated 500 million people. The parasite is found in soil and water, and it can be spread through contact with contaminated feces. Amebiasis often causes diarrhea, abdominal pain, and fever. Left untreated, it can lead to serious health problems such as liver abscesses or even death.
Metronidazole:
Metronidazole is an antibiotic used for the treatment of parasitic infection. It's mechanism of action is by inhibiting bacterial protein synthesis. The drug was first developed in 1960 and approved by the FDA in 1961 for use as an anti-parasitic agent.
Paromomycin:
Paromomycin is a semi-synthetic aminoglycoside antibiotic used to treat several bacterial infections. It works by inhibiting protein synthesis in the bacteria. The drug has excellent anti-bacterial activity and is characterized by good safety profile with low toxicity levels. Paromomycin was approved for use in the U.S.
Application Insights:
The hospital segment dominated the market in 2017. The application of metronidazole is more predominant in this segment as compared to other segments owing to its effectiveness against amebiasis and high usage rate. Hospital application was followed by pharmacy applications.
Amebiasis treatment with paromomycin is effective against both cyst and larvae stages of the disease, which makes it a preferred drug for treating amebiasis among others that are only effective against cyst stage such as tinidazole or miltefosine. However, due to higher cost associated with its use, preference is given towards using metronidazole over paromomycin for treating amebic colitis while hospitalized patients receive intensive care unit (ICU) treatment along with medication administered through a vein or directly into the stomach via an NG tube at the time of admission.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing prevalence of amebiasis and other associated conditions, such astravel-related infections, Crohn’s disease, and ulcerative colitis. In addition, rising number of product launches by key companies is also one of the major factors contributing toward regional growth. For instance; in May 2018; FlectorGel launched Tinidazole gel for oral administration in adults and children over 12 years of age suffering from acute Amebic Meningitis (AM).
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to increasing healthcare expenditure & government initiatives pertaining towards control & prevention of infectious diseases including amebiasis.
Growth Factors:
- Increasing awareness about the disease and its symptoms will drive the market growth.
- Rising incidence of amebiasis across the globe will fuel the demand for amebiasis therapeutics.
- Growing number of research and development activities for novel drug therapies will propel market growth.
- Technological advancements in diagnosis and treatment of amebiasis will provide lucrative opportunities for market players.
Scope Of The Report
Report Attributes
Report Details
Report Title
Amebiasis Market Research Report
By Type
Metronidazole, Paromomycin, Tinidazole, Other
By Application
Hospital, Pharmacy
By Companies
Dr. Reddy’s Laboratories, Mission Pharmacal, Aceto Corporation, Mylan Pharmaceuticals, Impax Laboratories, Pfizer, Sanofi, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceutical, Dr. Reddy’s Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
210
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Amebiasis Market Report Segments:
The global Amebiasis market is segmented on the basis of:
Types
Metronidazole, Paromomycin, Tinidazole, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy’s Laboratories
- Mission Pharmacal
- Aceto Corporation
- Mylan Pharmaceuticals
- Impax Laboratories
- Pfizer
- Sanofi
- Lupin Pharmaceuticals
- Glenmark Pharmaceuticals
- Sun Pharmaceutical
- Dr. Reddy’s Laboratories
Highlights of The Amebiasis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Metronidazole
- Paromomycin
- Tinidazole
- Other
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Amebiasis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Amebiasis is an infection caused by the protozoan parasite Entamoeba histolytica. Amebiasis can affect any part of the body, but is most commonly found in the large intestine. Amebiasis can cause severe diarrhea and abdominal pain, and may lead to liver abscesses or even death.
Some of the major players in the amebiasis market are Dr. Reddy’s Laboratories, Mission Pharmacal, Aceto Corporation, Mylan Pharmaceuticals, Impax Laboratories, Pfizer, Sanofi, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Sun Pharmaceutical, Dr. Reddy’s Laboratories.
The amebiasis market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Amebiasis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Amebiasis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Amebiasis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Amebiasis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Amebiasis Market Size & Forecast, 2018-2028
4.5.1 Amebiasis Market Size and Y-o-Y Growth
4.5.2 Amebiasis Market Absolute $ Opportunity
Chapter 5 Global Amebiasis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Amebiasis Market Size Forecast by Type
5.2.1 Metronidazole
5.2.2 Paromomycin
5.2.3 Tinidazole
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Amebiasis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Amebiasis Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Amebiasis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Amebiasis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Amebiasis Analysis and Forecast
9.1 Introduction
9.2 North America Amebiasis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Amebiasis Market Size Forecast by Type
9.6.1 Metronidazole
9.6.2 Paromomycin
9.6.3 Tinidazole
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Amebiasis Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Amebiasis Analysis and Forecast
10.1 Introduction
10.2 Europe Amebiasis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Amebiasis Market Size Forecast by Type
10.6.1 Metronidazole
10.6.2 Paromomycin
10.6.3 Tinidazole
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Amebiasis Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Amebiasis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Amebiasis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Amebiasis Market Size Forecast by Type
11.6.1 Metronidazole
11.6.2 Paromomycin
11.6.3 Tinidazole
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Amebiasis Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Amebiasis Analysis and Forecast
12.1 Introduction
12.2 Latin America Amebiasis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Amebiasis Market Size Forecast by Type
12.6.1 Metronidazole
12.6.2 Paromomycin
12.6.3 Tinidazole
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Amebiasis Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Amebiasis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Amebiasis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Amebiasis Market Size Forecast by Type
13.6.1 Metronidazole
13.6.2 Paromomycin
13.6.3 Tinidazole
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Amebiasis Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Amebiasis Market: Competitive Dashboard
14.2 Global Amebiasis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy’s Laboratories
14.3.2 Mission Pharmacal
14.3.3 Aceto Corporation
14.3.4 Mylan Pharmaceuticals
14.3.5 Impax Laboratories
14.3.6 Pfizer
14.3.7 Sanofi
14.3.8 Lupin Pharmaceuticals
14.3.9 Glenmark Pharmaceuticals
14.3.10 Sun Pharmaceutical
14.3.11 Dr. Reddy’s Laboratories
